Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Tectonic Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Tectonic Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:19 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212016
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $20,871 | $13,036 |
| General and administrative | 6,430 | 5,262 |
| Total operating expenses | 27,301 | 18,298 |
| Loss from operations | (27,301) | (18,298) |
| Other income (expense): | ||
| Interest income | 2,181 | 2,444 |
| Interest expense | (8) | (20) |
Item 1. Financial Statements.
FAQ
- What is Tectonic Therapeutics's R&D?
- Tectonic Therapeutics (TECX) reported R&D of $20.87M in Q1 2026.
- How has Tectonic Therapeutics's R&D changed year-over-year?
- Tectonic Therapeutics's R&D increased by 60.1% year-over-year, from $13.04M to $20.87M.
- What is the long-term trend for Tectonic Therapeutics's R&D?
- Over 4 years (2021 to 2025), Tectonic Therapeutics's R&D has grown at a -6.5% compound annual growth rate (CAGR), from $83.11M to $63.49M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Tectonic Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude